Optimizing Anemia Management and Addressing Unmet Needs in LR MDS
EP: 1.ESA-Ineligible LR MDS patient with Transfusion-Dependent Anemia
EP: 2.Therapy Selection for ESA Ineligible LR-MDS Patients
EP: 3.Mechanism of Action: Imetelstat in LR MDS
EP: 4.Efficacy and Safety of Imetelstat in ESA- ineligible patients
EP: 5.Adverse Event Profile & Management of Imetelstat
EP: 6.Comparing Telomerase Inhibitors and EMAs in ESA-Ineligible LR MDS
EP: 7.74- year-old man with LRMDS and Transfusion Dependent Anemia
EP: 8.Efficacy and Safety of 2L therapies for RS+ patients
EP: 9.EMA vs Telomerase Inhibitor for RS+ patients after ESA failure
Now Viewing
EP: 10.Optimizing Anemia Management and Addressing Unmet Needs in LR MDS
- Please share your key takeaways for optimizing anemia management in lower-risk MDS, and where do you see the most significant unmet needs?
- What remain the key unmet needs in treating anemia and improving outcomes for lower-risk MDS patients despite the availability of therapies like imetelstat, luspatercept, and ESAs?
- Are there any emerging agents, combination regimens, or ongoing trials in the pipeline?
Recent Videos
Related Content
AFFINITY Study Completes Enrollment for Novel Aliya PEF System in Advanced Lung Cancer
August 9th 2024Article
The AFFINITY study has finished enrolling participants to evaluate the Aliya pulsed electric field system in patients with stage IV non–small cell lung cancer or lung metastases who are not candidates for surgery.
Read More
